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Telomerase-pulsed dendritic cells: preclinical results and
outcome of a clinical phase I/II trial in patients with
metastatic renal cell carcinoma
Telomerase-beladene dendritische Zellen: Resultate einer klinischen
Phase I/II-Studie bei Patienten mit metastasierendem
Nierenzellkarzinom
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Objective: Therapeutic vaccination with dendritic cells (DC) showed
promising results in first clinical trials in cases of metastatic renal cell
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Design: 10 patients with progressive metastatic RCC were enrolled in
a clinical phase I/II trial using DC pulsed with hTERT-peptide. Beside Christian Franchy
5
AlexandervonRuecker
6
toxicity and feasibility aspects, a complex immune monitoring including
Holger Strunk
7 in vitro data were evaluated. In addition to detection of tumor-specific
effector cells we investigated their functionality like IFN-γ secretion and
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Results: The vaccine was well tolerated. Two patients showed a mixed
response (MR) and one patient a stable disease (SD). Interestingly, re- Thorsten Sommer
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sponders showed cytotoxic activity already before start of therapy and Tilman Sauerbruch
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there was a significant increase in cytotoxic activity of effector cells
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1 from all responders (SD and MR patients) after the first vaccination. In
contrastnon-respondersshowednocytotoxicactivitybeforeandduring
treatment. Therefore, cytotoxic activity might be used as a predictive
marker in the future. Tetramer staining detected higher amounts of tu- 1 University of Bonn,
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mor-specific cytotoxic cells in responding patients compared to non-re-
sponders. Also, responders possessed increasing amounts of IFN-γ
producing immunological effector cells.
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Conclusion: Telomerase-pulsed DC could enhance a tumor-specific im-
mune response against RCC.
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Zusammenfassung
Ziel: Therapeutische Impfungen mit Antigen-beladenen dendritischen
Zellen (DC) zeigten in ersten klinischen Versuchen bei Patienten mit
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nisse. Die menschliche Telomerase-reverse-Transkriptase (hTERT)
könnteeinmöglichesZielantigensein,dasiein85%allermenschlichen
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Methodik: 10 Patienten mit fortschreitend metastasierendem RCC
wurden in einer klinischen Phase I/II-Studie untersucht, nachdem sie
mehrereintratumoraleImpfungenaushTERT-beladenenautologenDCs 7 University of Bonn, Institute
of Radiology, Bonn, Germany erhaltenhaben.NebenÜberprüfungderVerträglichkeitwurdenverschie-
denste in vitro Analysen durchgeführt, die Aussagen über den Immun-
status der Patienten geben sollen. Hierbei wurde sowohl nach tumor-
spezifischen Effektorzellen geschaut, als auch deren Funktionalität in
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untersucht.
Ergebnisse: Die Impfungen wurden von allen Patienten gut vertragen.
Zwei Patienten zeigten eine Mischantwort (MR) mit Rückbildung der
punktierten Metastase und ein Patient zeigte eine Stabilisierung (SD)
mit unverändertem Krankheitsverlauf. Erstaunlicherweise konnte bei
denansprechendenPatientenschonvorStudienbeginneineZytotoxizität
vonEffektorzellennachgewiesenwerden,dienachder1.Impfungsigni-
fikantanstieg.Demgegenüberzeigtendienicht-ansprechendenPatien-
ten vor, während und nach der Behandlung keine zytotoxische Aktivität
gegenüber Tumorzellen. Folglich könnte die Zytotoxizität von Effektor-
zellen in Zukunft als Prognosemarker verwendet werden. Die anspre-
chenden Patienten besaßen im Vergleich zu den nicht-ansprechenden
Patienten eine höhere Anzahl an Tumor-spezifischen zytotoxischen
Zellen sowie IFN-γ produzierenden Effektorzellen.
Schlussfolgerung: Wir konnten zeigen, dass eine Impfung mit Telome-
rase-beladenen autologen DCs eine in geringem Ausmaß vorhandene
Tumor-spezifische Immunantwort signifikant verstärken kann.
Schlüsselwörter: Dendritische Zellen, Telomerase, Immuntherapie,
Nierenzellkarzinom, T-Zell-Antwort
Introduction
Metastatic RCC has a poor prognosis with a median sur-
vival of less than one year [1]. Systemic treatment with
cytotoxic chemotherapy is usually ineffective. Since RCC
is known for its immunological susceptibility [2], several
immunotherapeuticalapproacheshavebeendeveloped.
These include immunomodulatory cytokines, allogeneic
blood stem cell transplantation [3] and vaccination with
DC [4], [5]. DC are the most potent stimulators of T
lymphocytes and are therefore expected to be of great
importance in the antitumoral immune response. Re-
cently, DC were used in several studies to increase the
cytotoxicactivityofimmunologiceffectorcellsinvitroand
in vivo [6], [7], [8].
Telomerase is a ribonucleoprotein enzyme that plays a
keyroleinmaintainingchromosomalstabilityandcellular
life span. Three components of human telomerase, hu-
man telomerase RNA component (hTERC), human te-
lomerase protein 1 (hTEP1) and human telomerase re-
verse transcriptase (hTERT) have been identified. hTERT,
the catalytic subunit of human telomerase, is expressed
in 85% of human cancers but usually not in normal cells.
Therefore, it seems to be an ideal candidate for an ubi-
quitous, specific tumor-associated antigen. Different
antigenic epitopes from hTERT inducing tumor-specific
cytotoxic T lymphocytes have been described [9], [10],
[11].
Various clinical observations have suggested that the
immune system may influence the prognosis of RCC.
Unfortunately, in most patients the immune response to
RCC is insufficient to control the disease. Although im-
munotherapeutical approaches to RCC have been prom-
ising, only a small number of patients could benefit from
these treatments. This is discussed as tumor-induced
immunosuppression,whichinfluencestheimmunestatus
by raising the activation threshold or inducing anergy
[12].Thiscouldbecrucialfortheoutcomeoftheindividu-
al patient and might be predictive for the success of im-
munotherapy. Immunotherapeutic strategies have so far
only sometimes lead to clinical responses. Therefore, a
predictivemarkerforresponsewouldbeofmajorimport-
ance.
Here, we present in vitro data and results of a clinical
phase I/II trial using DC pulsed with telomerase-peptide
in patients with progressive metastatic renal cell car-
cinoma.
Patients and methods
Patient characteristics and evaluation
PatientswithprogressivemetastaticRCC,Karnofskyscore
of 60%-100% and a haplotype of either HLA-A2, HLA-A3
or HLA-A24 were eligible for this study. Exclusion criteria
included a time interval of less than 28 days to previous
chemotherapy or cytokine treatment, severe heart dis-
ease, severe psychiatric disease, active hepatitis A, B, or
C and HIV infection. Approval of local ethics committees
was obtained (AZ 110/02).
Ten patients were enrolled in our clinical protocol (Table
1). Median age was 63.5 years (range 47 to 74) and all
patients were male. Four patients had metastases in the
lung, seven patients had bone metastases, four had
metastases in lymph nodes, three had liver metastases
and five patients had metastases in other viscera. The
patients had an average score of 1.0 according to prog-
nosticfactors(prognosticscaleof0-2).Prognosticfactors
were calculated as determined by the Multicenter Group
for Treatment of RCC based on serum level of CRP and
LDH, number of neutrophil count, number of metastatic
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sites, presence of bone metastases and time from dia-
gnosis of tumor to metastatic disease [13].
Generation of dendritic cells
DC were generated according to the protocol published
bySchuleretal.[14].Inbrief,peripheralbloodmononucle-
arcells(PBMC)fromleukopheresisproductswereisolated
by Ficoll density gradient centrifugation. After two adhe-
sion steps cells were cultivated in RPMI media with 750
U/mlGM-CSFand500U/mlIL-4.Maturationwasinduced
using 1000 U/ml TNF-α, 750 U/ml IL-6, 100 U/ml IL-1β
and 1 µg/ml PGE2. Cells were harvested on day +8 and
frozenataliquotsof0.5-1.5x10
7cells/mlin90%autolog-
ous serum and 10% DMSO. On the day of vaccination,
10
6 DC were pulsed with 10µg of the respective te-
lomerase peptide HLA-A*02: ILAKFLHWL, HLA-A*03:
KLFGVLRLK,HLA-A*24:VYAETKHFLfromJeriniAG(Berlin,
Germany) and 50 µg/ml endotoxin free KLH as adjuvant
for 2 hours at 37°C. The maturation state of DC was
controlled by flow cytometry.
Treatment of patients
All patients had been nephrectomied before start of vac-
cination. One half of DC was administered intradermally,
theotherhalfofthevaccinewasinjecteddirectlyintothe
tumor under CT-guidance. This procedure was repeated
on days 8, 22, 36 and 50. One patient only received
intradermalapplications.Inmostcases,patientsreceived
1-2x10
7 cells per vaccine. In addition, a low dose of IL-2
(4x10
6IU/perday;Proleukin
®S,Chiron-Behring,Marburg,
Germany) was given on days 1-28. However, this dose
was not tolerated in all patients.
Clinical outcome
Medical history was taken and the following baseline
studies were performed before starting the treatment:
physical examination, full blood count, blood chemistry
basics and urine analysis. Blood was also subjected to
immunologicalcomprehensivetestingasdescribedbelow.
Chest X-rays and CT scans of chest and abdomen were
taken. Clinical assessment was repeated on days 8, 22,
36 and 50, a complete clinical and immunological
screening comparable to the initial check-up was per-
formed on day 50. Stable disease was defined as a de-
crease of measurable tumor manifestations of less than
50%oranincreaseoflessthan25%[15]andaconstant
number of bone lesions. ‘Measurable tumor manifest-
ations’ refers to diameters as determined in CT scans.
Immunological studies
Delayed-type hypersensitivity (DTH)
To test for a telomerase-specific immune response, 10
µg from the corresponding telomerase peptide were ad-
ministered intradermally before and after treatment. A
positive skin-test reaction was defined as an induration
of more than 2 mm in size after 48 hours.
Preparation of peripheral blood lymphocytes
(PBL)
PBL were obtained and isolated from heparinized peri-
pheral blood by centrifugation with BD Vacutainer CPT
Cell Preparation Tubes
®. Cells were cryo-preserved for
further analysis.
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Fresh peripheral blood from patients and from healthy
donors of similar age was stained using various mono-
clonal antibodies directed against human cell surface
antigens, including those against human CD1a, CD3,
CD4, CD8, CD11c, CD13, CD14, CD16, CD19, CD23,
CD25, CD28, CD40, CD56, CD62, CD69, CD80, CD83,
CD86, CD123, CD154, CD158a, CD158b, and HLA-DR
(Immunotech Hamburg, Germany; BD Biosciences
Pharmingen, Heidelberg, Germany; Beckman Coulter,
Krefeld, Germany). In addition, patients’ blood was
screened for the presence of peptide-specific cells. Tet-
ramers specific for the respective telomerase peptides
were purchased from ProImmune (Oxford, U.K.). Freshly
drawn blood was stained with tetramers and antibody
against CD8.
In addition, DC were generated as outlined above and
stained for CD1a, CD14, CD40, CD80, CD83 and CD86
(Immunotech Hamburg, Germany; BD Biosciences
Pharmingen, Heidelberg, Germany; Beckman Coulter,
Krefeld, Germany).
Analysis was performed on a BD FACSCalibur
TM.
Cytotoxicity assay
A standard chromium release assay was used to deter-
mine the cytotoxic activity of PBL. In brief, T2 target cells
were loaded with 50 µg/ml from the corresponding HLA-
A*02 telomerase peptide and then labeled with 100 µCi
51Cr for two hours. HLA-matched allogeneic RCC cells as
target cells were directly labeled with 100 µCi
51Cr for two
hours. 5000 target cells per well were incubated with
PBL at different effector to target cell ratios. After four
hours, the supernatant was collected and counts per
minuteweredetermined.Eachexperimentwasperformed
intriplicateandthemeanvaluewascalculated.Maximum
release was obtained by incubating the target cells with
0.1% IGEPAL
® (anionic detergent from Sigma). Target
cells without effector cells served as a negative control
(spontaneous release). Cytotoxicity calculations were
performed using the following formula:
Proliferation assay
The non-radioactive proliferation assay „EZ 4 U“ (Bio-
medica, Vienna, Austria) was performed according to the
manufacturer’s instructions. PBMC were stimulated with
5 µg/ml of the respective telomerase peptide for three
hours. PBL were harvested and the proliferation rate of
2.5x10
4 cells was determined in triplicate after 24 hrs as
the amount of turnover of yellow tetrazolium salt to red
formazon. Absorbance at 490 nm was measured with an
ELISA reader.
Analysis of IFN-γ producing immunological
effector cells using ELISpot assay
IFN-γ production of PBL was determined using a human
IFN-γELISpotkitaccordingtothemanufacturer’sinstruc-
tions (Hölzel, Cologne, Germany). In brief, PBMC were
stimulated with 5 µg/ml of the respective telomerase
peptideoverthreehours.PBLwereharvestedandplated
onnitrocellulose96-wellplatesinduplicates.IFN-γsecre-
tion of 2.5x10
4 cells was determined after 48 hrs. Spot
analysis was performed using the KS 400 system (Carl
Zeiss, Jena, Germany).
Statistical analysis
Nonparametricalanalysis(Mann-Whitney-Utest)onSPSS
11.5 was used to analyze statistical significance. A
p-value <0.05 was considered significant.
Results
Expression of cell surface antigens on
DC
DC were generated as reported in the materials and
methodssection.DCwerestainedforvariouscellsurface
antigensandmeasuredbyflowcytometry.BothDCofthe
first vaccine and of the following vaccines (2.-5.) are
shown in Figure 1. DC showed high expressions of DC
typical markers such as CD1a, CD40, CD80, CD83 and
CD86. In contrast, expression of CD14 was low (Figure
1).
Cytotoxicity of PBL collected during
treatment
The cytotoxic effect of PBL during the treatment was
monitoredusingpeptide-loadedT2cellsorHLA-matched
allogeneic RCC cells as targets. PBL from responders al-
ways showed a significantly higher cell lysis compared to
cells from non-responders. This was true even before
vaccination.Non-respondernevershowedanyremarkable
lysis (Figure 2). Responders also showed a significant
increase in cytotoxic activity after the first vaccination
comparedtotheinitialsituation(p=0.043;Figure3).This
activity dropped below the initial level after the first vac-
cination and then increased.
Number of leukocytes
Interestingly, the number of leukocytes was increased in
non-responders compared to healthy donors. This was
significant at most times (Figure 4). The number of
granulocytes was increased significantly in non-respon-
ders compared to healthy donors. The number of
granulocytes was higher in non-responders compared to
responders before, during and after the trial (Figure 5).
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DC were generated as reported in the materials and methods section. DC were stained for various cell surface antigens and
measured by flow cytometry. Both DC of the first vaccine and of the following vaccines (2.-5.) are shown. Results are presented
as mean of the different groups +/- standard error.
Figure 2: Cytotoxicity assay of PBL from Non-Responder
PBL were obtained from patients before, during and after treatment and investigated in a standard chromium release assay. A
p-value <0.05 was labeled with an asterisk and means a significant increase in cytotoxic activity after the first vaccination
compared to the initial situation. Results are presented as mean of the different groups.
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PBL were obtained from patients before, during and after treatment and investigated in a standard chromium release assay. A
p-value <0.05 was labeled with an asterisk and means a significant increase in cytotoxic activity after the first vaccination
compared to the initial situation. Results are presented as mean of the different groups.
Figure 4: Number of leukocytes
Blood was drawn from patients before, during and after treatment and cell numbers were determined by FACS analysis. A p-value
<0.05 was labeled with an asterisk. Results are presented as mean of the different groups.
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Blood was drawn from patients before, during and after treatment and cell numbers were determined by FACS analysis. A p-value
<0.05 was labeled with an asterisk. Results are presented as mean of the different groups.
Figure 6: Proliferation assay of PBL
PBMCwereobtainedfrompatientsbefore,duringandaftertreatment.Mononuclearcellswerestimulatedwithtelomerasepeptide
and lymphocytes were investigated in an MTT proliferation assay. The OD (optical density) was determined at 450 nm. A p-value
<0.05 was labeled with an asterisk. Results are presented as mean of the different groups.
Proliferation of PBL
Proliferationtendedtobehigherinresponderscompared
to non-responders. This was significant after the second
vaccination (Figure 6, p=0.033).
ELISpot results
Numbers of IFN-γ producing cells increased during vac-
cinationwithpeaksafterthethirdandfourthvaccination.
This phenomenon was significantly higher in responders
(SD and MR patients) compared to non-responders
(p=0.03; Figure 7). Numbers of cells remained elevated
after completion of the trial.
Tetramer analysis
In responders, numbers of telomerase-specific cytotoxic
cells(CD3+CD8+)increasedduringvaccinationcompared
to numbers before treatment with a peak after the third
vaccination (Figure 8). These data tend to correlate with
the ELISpot results (p= 0.06).
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PBMCwereobtainedfrompatientsbefore,duringandaftertreatment.Mononuclearcellswerestimulatedwithtelomerasepeptide
andlymphocyteswereinvestigatedforIFN-gammasecretion.Ap-value<0.05waslabeledwithanasterisk.Resultsarepresented
as mean of the different groups.
Figure 8: Tetramer analysis
Patients' blood was screened for telomerase-specific cytotoxic T cells before, during and after treatment. Cells were stained using
tetramers. Cells from healthy donors were used as negative control. Data are shown as mean of the different groups.
Patient outcome
With respect to our protocol, clinical outcome was based
on a comparison of CT scans before and after treatment,
i.e. three months after entering the protocol. All ten pa-
tients were in progressive disease when entering our
protocol. 2/10 patients showed a mixed response (MR)
with tumor regression at the site of DC injection and
progress of the untreated tumor. One patient showed a
stable disease (SD) after vaccination and 7/10 patients
remained in progressive disease (PD). The two patients
belongingtoprognosticgroup0(goodprognosis)respond-
ed with SD or with MR, respectively. Of prognostic group
1,fiveofsixpatientsremainedinprogression,onepatient
showed a MR. Of prognostic group 2 (poor prognosis),
both patients remained in progression (Table 2). MR
lasted for 92 and 145 days, respectively. SD lasted for
180 days. In general, the vaccine was well tolerated in
all patients and no toxicity was observed. However, three
patientsdiedduetoprogressionoftumorgrowthondays
59, 64, and 100 after start of treatment, respectively.
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DTH reactivity
DTH testing using telomerase peptide was performed
beforeandaftertreatment.2/8patientsshowedreactivity
after vaccination (Table 2).
Discussion
There is an urgent need for new therapeutic approaches
fortreatmentofmetastaticrenalcellcarcinoma.Immuno-
therapycouldbeapotentialwaytotreatthisimmunogen-
ic tumor entity, where telomerase could be a suitable tu-
mor-associated antigen (TAA) [16]. So far, no other TAAs
were found to have a major impact in immunotherapeut-
ical approaches in RCC.
Here, we present data from a clinical phase I/II study
using telomerase peptide-pulsed DC. This vaccination
protocol was shown to be safe and feasible, although,
unfortunately, three patients died during therapy due to
rapid progression of disease. Although the clinical out-
comewasnotthemainfocusofthisstudy,westagedthe
patients after a follow-up of three months. 2/10 patients
showed a MR, 1 patient had a SD for a median of 6
months.
The main focus of this trial was the complex immune
monitoring. We compared the patients with MR and SD
(responder) with patients with PD (non-responder) by
statisticalanalysis.Interestingly,wesawsignificantdiffer-
ences in the immunological data between responders
and non-responders. The most relevant result was the
differenceincytotoxicactivityofPBLbetweenresponders
and non-responders. Responders showed cytotoxic
activitypriortotherapy,whichcouldbeenhancedfurther.
Incontrast,effectorcellsofnon-responderswerenotable
tolyseallogeneicRCCandpeptide-loadedT2cellsatany
time.Similarresultswereobtainedinotherclinicaltrials,
where we used tumor lysate-pulsed DC or DC fused with
tumor cells for vaccination [17].
Ingeneral,weobservedastatisticallysignificantincrease
in granulocytes and leukocytes in non-responders. How-
ever, an elevated number of leukocytes was not accom-
panied by an increase in activity. PBL from non-respond-
ers generally showed lower proliferation rates and lower
numbers of IFN-γ secreting cells after antigen restimula-
tion. Also, we observed an increase in antigen-specific
cytotoxic T cells and in IFN-γ secreting cells during ther-
apy, which was more prominent in responders.
In our cytotoxicity experiments, we observed a decrease
inactivityafterthesecondvaccination.Thismightindicate
adownregulationinimmunologicalfunction,whichcould
be due to the fact that the interval between 1
st and 2
nd
was short (1 week).
Our protocol included both intradermal and intratumoral
injectionofpeptide-loadedDC.Interestingly,patientswho
showed a MR had tumor regression at the site of DC in-
jection.Thisisinaccordancewithdatafromothergroups
whoobservedagoodresponseafterlocaladministration
of interleukin-2 [18]. The patient who had a stabilization
of disease received no intratumoral injection due to
technicalreasons.Therefore,weconcludethatintratumor-
al injection has a locally limited effect whereas
intradermal injection leads to systemic activation.
Mostinterestingly,allnon-respondersshowednocytotoxic
activityatanytimeduringthestudy.Incontrast,respond-
ers showed cytotoxic activity before start of therapy. This
could be enhanced during the study. Therefore, cytotoxic
activitymayserveasapredictivemarkerforimmunologic
function.
In conclusion, the protocol described has produced en-
couragingresultsconcerningtoxicityandfeasibilityofDC-
based vaccines in RCC. In addition, this study shows a
potential role for cytotoxic activity of patients' effector
cells as predictive marker. This aspect will be evaluated
in further studies.
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